Yuhan Corporation is trading at 57,500 KRW as of 11:30 AM on the 4th, down 1.71% from the previous day. The trading volume is 433,279 shares, which is about 19.71% of the previous day's volume. Yuhan Corporation is known as one of the leading domestic pharmaceutical companies specializing in prescription drugs.

On August 3rd, Minjeong Seon, a researcher at Hana Financial Investment, stated, "If this clinical trial succeeds, the market size and value of the drug Lezatinib are expected to increase significantly," and set Yuhan Corporation's target price at 82,000 KRW.

Over the past five days, individual investors have net purchased 292,136 shares of Yuhan Corporation, while foreigners and institutions have net sold 148,412 shares and 185,818 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.




This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing